ImmunityBio Reports Strong ANKTIVA Sales Growth and Secures First Global NSCLC Approval with Subcutaneous Administration
IBRX sits 70% above its 52-week low of $1.83 on elevated volume (3.8× avg).
Summary
ImmunityBio announced robust preliminary Q4 and full-year 2025 product revenue, driven by ANKTIVA sales, alongside a landmark Saudi FDA approval for ANKTIVA in non-small cell lung cancer, marking its first global approval for this indication and subcutaneous use.
Key Events · Product Development and Regulatory · IBRX
-
Record ANKTIVA Revenue Growth
Preliminary net product revenue for FY2025 reached approximately $113.0 million, a 700% increase year-over-year, with Q4 2025 revenue at $38.3 million, up 20% quarter-over-quarter.
-
Landmark NSCLC Approval
The Saudi FDA granted approval of ANKTIVA in combination with immune checkpoint inhibitors for metastatic non-small cell lung cancer, representing the first global approval for this indication and the first for subcutaneous administration.
-
Expanded NMIBC Approval
The SFDA also approved ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, adding to existing approvals in the U.S. and U.K.
-
Strong Cash Position
The company ended Q4 2025 with an estimated $242.8 million in cash, cash equivalents, and marketable securities.
Analysis · IBRX · Life Sciences
This 8-K filing signals significant positive momentum for ImmunityBio, driven by both strong commercial execution and key regulatory advancements. The substantial year-over-year and quarter-over-quarter revenue growth for ANKTIVA demonstrates increasing market adoption and commercial success. Crucially, the Saudi FDA's approval of ANKTIVA for non-small cell lung cancer, particularly as the first global approval for this indication and for subcutaneous administration, opens a new, potentially large market and enhances the drug's versatility and patient convenience. This approval validates the broader applicability of ImmunityBio's platform beyond bladder cancer. The solid cash position further supports ongoing development and commercialization efforts, reducing near-term financing concerns. Investors should monitor the continued commercial ramp-up of ANKTIVA and the progress of the NSCLC launch, as well as further regulatory expansions.
At the time of this filing, IBRX was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $1.83 to $4.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.